Understanding MPNs: Accessing the Best Care & Treatment Options

A Town Meeting for Patients, Care Partners and Families

May 05, 2018



An audience of MPN patients and their caregivers joined us at a recent town meeting along with the University of Colorado Anschutz Medical Campus to hear the latest treatment and research news, inspiring stories of people living well with MPNs, tips for effective communication with a healthcare team and more.

We are also planning events in other cities. If you haven’t already, please sign up for email updates so we can alert you when important and inspiring videos become available and when upcoming town meetings are scheduled.

 

Patient Folder


Special thanks to our promotional partners, MPN Research Foundation, The Leukemia & Lymphoma Society (LLS), Canadian Myeloproliferative Neoplasm Network, PV Reporter, MPN Alliance Australia, MPN Advocacy & Education International and MPN Cancer Connection for their help with this program. The logos for each of these organizations, linked to their individual websites, can be found below.


Regulating the Course of MPNs: What Are Inhibitors and How Do They Work?

Can modern MPN treatments disrupt the abnormal molecular signaling in cancerous cells? A panel of MPN experts discuss pathway inhibitors and their effect on proliferative activity and disease course. Watch now to learn more.

Published:

The Clinical Trial Process: An Explanation of How Efficacy and Patient Safety Are Monitored

A panel of experts explain the layers of review, or clinical trial phases, that go into the development of new therapies. How are MPN patients protected throughout the process? Watch now to also learn about safeguards in place before and during the study.

Published:

Understanding MPNs: Experts Explain Essential Thrombocythemia, Myelofibrosis and Polycythemia Vera

MPN experts, Lindsey Lyle and Dr. Brandon McMahon, explain how ET, MF and PV manifest in the body, distinguishing features of each disease, key indicators doctors look for upon diagnosis, and more. Watch now to learn about the characteristics of MPNs.

Published:

Determining Risk: What Testing and Genetic Mutations Reveal About Your MPN

Dr. Naval Daver gives expert insight into getting a definitive MPN diagnosis, distinguishing between ET, PV and MF, and the role of genetic mutations in diagnostics, progression and finding an effective treatment plan.

Published:

Expert Perspective: Encouraging Research Developments in the Treatment of MPNs

On location at an MPN town meeting in Colorado, Dr. Naval Daver from MD Anderson Cancer Center discussed the latest developments in MPN treatment, including research in combination therapies.

Published:

Hope and Progress in MPN Treatment: Updates From an Expert

On location at the University of Colorado Anschutz Medical Campus, Dr. Brandon McMahon shares an update on the progress being made in the treatment landscape for myeloproliferative neoplasms (MPNs).

Published:

Session 2 Replay - Understanding MPNs: Accessing the Best Care & Treatment Options

The recent MPN town meeting in partnership with the University of Colorado Anschutz Medical Campus featured renowned MPN experts and clinicians discussing living well with an MPN and responding to audience questions.

Published:

Session 1 Replay - Understanding MPNs: Accessing the Best Care & Treatment Options

The recent MPN town meeting in partnership with the University of Colorado Anschutz Medical Campus featured renowned experts and clinicians discussing access to the best care and treatment options for those living with MPNs.

Published:

Host & Guests
Host

Host, Patient Power Co-Founder, Two-Time Cancer Survivor and MPN Patient Advocate


Guests

This town meeting was sponsored by Incyte Corporation. It was produced by Patient Power in partnership with the University of Colorado Anschutz Medical Campus.


 

 

 

 

 

Patient Power
University of Colorado Anschutz Medical Campus
Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on July 10, 2018